RTTNews | Mar 8, 2021 07:10AM EST

07:09 Monday, March 8, 2021 (RTTNews.com) - Shares of implantable visual prosthetic maker Second Sight Medical Products, Inc. (EYES) are rising more than 16% in pre-market trading on Monday.

Friday, the company had announced that the FDA approved its Argus 2s Retinal Prosthesis System for the treatment of retinitis pigmentosa (RP), a genetic disorder, that affects cells in the retina leading to loss of sight.

Argus 2s is a set of external hardware, glasses and video processing unit, to be used in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa.

Argus II System provides electrical stimulation that bypasses the defunct retinal cells and stimulates remaining viable cells inducing visual perception in people with severe to profound RP.

EYES gained more than 300% on Friday, before closing at $5.79.

Read the original article on RTTNews ( https://www.rttnews.com/3175564/stock-alert-second-sight-medical-uptick-continues-in-pre-market.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved